Evidence map›Paper›PMID 38889324›Full record

ArticleBioconjugate chemistry2024

Increasing Signal Intensity of Fluorescent Oligo-Labeled Antibodies to Enable Combination Multiplexing.

Madeline E McCarthy, Xiaoming Lu, Oluwaferanmi Ogunleye, Danielle R Latham, Megan Abravanel, Daniel Pritko, Jonah R Huggins, Charlotte V Haskell, Nishi D Patel, Zachariah A Pittman and 2 more

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Madeline E McCarthyDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina 29634-0002, United States.ORCID 0000-0002-6367-0461
Xiaoming LuDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina 29634-0002, United States.
Oluwaferanmi OgunleyeDepartment of Chemistry, Clemson University, Clemson, South Carolina 29634-0002, United States.
Danielle R LathamDepartment of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634-0002, United States.
Megan AbravanelDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina 29634-0002, United States.
Daniel PritkoDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina 29634-0002, United States.
Jonah R HugginsDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina 29634-0002, United States.ORCID 0000-0001-7468-4626
Charlotte V HaskellDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina 29634-0002, United States.
Nishi D PatelDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina 29634-0002, United States.
Zachariah A PittmanDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina 29634-0002, United States.ORCID 0000-0002-9022-669X
Hugo SanabriaDepartment of Chemistry, Clemson University, Clemson, South Carolina 29634-0002, United States.ORCID 0000-0001-7068-6827
Marc R BirtwistleDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina 29634-0002, United States.ORCID 0000-0002-0341-0705

Funding

SINGLE MOLECULE ANALYSIS OF PSD-95 STRUCTURE AND LIGAND BINDINGR01MH081923 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI BOWEN, MARK E · 2008 to 2022
$5.6M
Mechanistic Pharmacodynamic Modeling for Drug Combination ResponsesR35GM141891 · NIGMS · CLEMSON UNIVERSITY · PI BIRTWISTLE, MARC R. · 2021 to 2025
$2.1M
Multiplexed, Quantitative Fluorescence Imaging in Tumor SectionsR21CA196418 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BIRTWISTLE, MARC R. · 2015 to 2017
$936k
Impact of pathogenic missense mutations on the ARID domain of ARID1aR15CA280699 · NCI · CLEMSON UNIVERSITY · PI SANABRIA, HUGO · 2023 to 2023
$443k
NCI NIH HHS R15 CA280699NCI NIH HHS R21 CA196418NIGMS NIH HHS R35 GM141891NIMH NIH HHS R01 MH081923
6 · The paper itself

Abstract

Full-spectrum flow cytometry has increased antibody-based multiplexing, yet further increases remain potentially impactful. We recently proposed how fluorescence multiplexing using spectral imaging and combinatorics (MuSIC) could do so using tandem dyes and an oligo-based antibody labeling method. In this work, we found that such labeled antibodies had significantly lower signal intensities than conventionally labeled antibodies in human cell experiments. To improve signal intensity, we tested moving the fluorophores from the original external (ext.) 5' or 3' end-labeled orientation to internal (int.) fluorophore modifications. Cell-free spectrophotometer measurements showed a ∼6-fold signal intensity increase of the new int. configuration compared to the previous ext. configuration. Time-resolved fluorescence and fluorescence correlation spectroscopy showed that the ∼3-fold brightness difference is due to static quenching most likely by the oligo or solution in the ext. configuration. Spectral flow cytometry experiments using peripheral blood mononuclear cells show int. MuSIC probe-labeled antibodies (i) retained increased signal intensity while having no significant difference in the estimated % of CD8+ lymphocytes and (ii) labeled with Atto488, Atto647, and Atto488/647 combinations can be demultiplexed in triple-stained samples. The antibody labeling approach is general and can be broadly applied to many biological and diagnostic applications where spectral detection is available.

Indexed as

AntibodiesFlow CytometryFluorescent DyesHumansLeukocytes, MononuclearSpectrometry, FluorescenceAntibodiesFluorescent Dyes

Identifiers

PMID38889324
PMCPMC11262307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.